Acta Scientific Otolaryngology (ASOL) (ISSN: 2582-5550)

Research Article Volume 4 Issue 6

Uveal Malignant Melanoma: A Case Report

Zahoor Ahmad Teli1, Rajesh A Kantharia2* and Shehnaz R Kantharia3

1Junior Consultant, Head and Neck Surgical Oncology, Kailash Cancer Hospital and Research Centre, Muni Seva Ashram, Goraj, India
2Medical Director and Head, Department of Head and Neck Surgical Oncology, Kailash Cancer Hospital and Research Centre, Muni Seva Ashram, Goraj, India
3Consultant, Otorhinolaryngology/Head and Neck Surgery, Kailash Cancer Hospital and Research Centre, Muni Seva Ashram, Goraj, India

*Corresponding Author: Rajesh A Kantharia, Medical Director and Head, Department of Head and Neck Surgical Oncology, Kailash Cancer Hospital and Research Centre, Muni Seva Ashram, Goraj, India.

Received: March 30, 2022; Published: May 13, 2022


Uveal malignant melanoma arises from melanocytes in the uveal tract of the eye which comprises of iris, ciliary body and choroid (common). It is the most common intraocular malignancy seen in Caucasian adults and is more in males than females. Early diagnosis and local treatment is crucial as survival correlates with primary tumor stage. Approximately 50% of the patients develop metastasis even after 20 years of diagnosis and may die in 6 to 12 months after the confirmation of metastatic disease, although the recurrence is infrequent. We report a case of malignant melanoma of uvea in 37 years old female.

Keywords: Uveal Malignant Melanoma; Choroid Melanoma; Enucleation; Melanocytes


  1. Chang AE., et al. “The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade”. The American College of Surgeons Commission on Cancer and the American Cancer Society”. Cancer 8 (1998): 1664-1678.
  2. McLaughlin CC., et al. “Incidence of noncutaneous melanomas in the U.S”. Cancer5 (2005): 1000-1007.
  3. Damato B. “Progress in the management of patients with uveal mela­noma: the 2012 Ashton Lecture”. Eye (Lond)9 (2012): 1157-1172.
  4. Virgili G., et al. “Incidence of uveal melanoma in Europe”. Ophthalmology 114 (2007): 2309-2315.
  5. Kivelä T. “The epidemiological challenge of the most frequent eye cancer: retinoblastoma, an issue of birth and death”. British Journal of Ophthalmology9 (2009): 1129-1131.
  6. Andreoli MT., et al. “Epidemiological trends in uveal melanoma”. British Journal of Ophthalmology11 (2015): 1550-1553.
  7. Weis E., et al. “The association between host susceptibility factors and uveal melanoma: a meta-analysis”. Archives of Ophthalmology1 (2006): 54-60.
  8. Krantz BA., et al. “Uveal melanoma: epidemiology, etiology, and treatment of primary disease”. Clinical Ophthalmology 11 (2017): 279-289.
  9. Damato EM and Damato BE. “Detection and time to treatment of uveal melanoma in the United Kingdom: an evaluation of 2,384 patients”. Ophthalmology8 (2012): 1582-1589.
  10. Shields CL., et al. “Metastasis of uveal melanoma millimeter-by-millimeter in 8033 consecutive eyes”. Archives of Ophthalmology8 (2009): 989-998.
  11. Edge SB., et al. “Malignant melanoma of the uvea”. In: AJCC Cancer Staging Manual, 7th Springer: New York, NY, USA (2010): 547-559.
  12. Tarlan B and Kıratlı H. “Uveal Melanoma: Current Trends in Diagnosis and Management”. Turkish Journal of Ophthalmology 3 (2016): 123-137.
  13. Shields JA., et al. “Pseudomelanomas of the posterior uveal tract: the 2006 Taylor R. Smith Lecture”. Retina6 (2005): 767-771.
  14. IW McLean., et al. “Reappraisal of Callender's spindle A type of malignant melanoma of choroid and ciliary body”. American Journal of Ophthalmology 86 (1978): 557-564.
  15. MJ Hendrix., et al. “Biologic determinants of uveal melanoma metastatic phenotype: role of intermediate filaments as predictive markers”. Lab Investigation 78 (1998): 153-163.
  16. S Kaliki and CL Shields. “Uveal melanoma: relatively rare but deadly cancer”. Eye 31 (2017): 241-257.
  17. Collaborative Ocular Melanoma Study Group. “The COMS randomized trial of iodine 125 brachytherapy for choroidalmelanoma: V. Twelve-year mortality rates and prognosticfactors: COMS report No. 28”. Archives of Ophthalmology12 (2006): 1684-1693.
  18. Kaliki S., et al. “Uveal melanoma: estimating prognosis”. Indian Journal of Ophthalmology2 (2015): 93-102.
  19. Singh AD., et al. “Uveal melanoma: Trends in incidence, treatment, and survival”. Ophthalmology 118 (2011): 1881-188
  20. Diener‑West M., et al. “Development of metastatic disease after enrollment in the COMS trials for treatment of choroidalmelanoma: Collaborative Ocular Melanoma Study Group Report No 26”. Archives of Ophthalmology 123 (2005): 1639-16
  21. Gragoudas ES., et al. “Survival of patients with metastases from uvealmelanoma”. Ophthalmology 98 (1991): 383-38


Citation: Rajesh A Kantharia., et al. “Uveal Malignant Melanoma: A Case Report".Acta Scientific Otolaryngology 4.6 (2022): 08-12.


Copyright: © 2022 Rajesh A Kantharia., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Acceptance rate34%
Acceptance to publication20-30 days
Impact Factor0.871

Indexed In

News and Events

  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is May 30, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue"
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.

Contact US